Cargando…
The Effect of IL-6 Inhibitors on Mortality Among Hospitalized COVID-19 Patients: A Multicenter Study
BACKGROUND: The effectiveness of interleukin-6 inhibitors (IL-6i) in ameliorating coronavirus disease 2019 (COVID-19) remains uncertain. METHODS: We analyzed data for patients aged ≥18 years admitted with a positive severe acute respiratory syndrome coronavirus 2 polymerase chain reaction test at 4...
Autores principales: | Sinha, Pranay, Jafarzadeh, S Reza, Assoumou, Sabrina A, Bielick, Catherine G, Carpenter, Bethanne, Garg, Shivani, Harleen, Sahni, Neogi, Tuhina, Nishio, Midori Jane, Sagar, Manish, Sharp, Veronika, Kissin, Eugene Y |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717300/ https://www.ncbi.nlm.nih.gov/pubmed/33216906 http://dx.doi.org/10.1093/infdis/jiaa717 |
Ejemplares similares
-
Clinical outcomes and inflammatory marker levels in patients with Covid-19 and obesity at an inner-city safety net hospital
por: Mostaghim, Anahita, et al.
Publicado: (2020) -
Relationship Between Hepatitis C Clinical Testing Site and Linkage to Care
por: Assoumou, Sabrina A., et al.
Publicado: (2014) -
Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge
por: Sinha, Pranay, et al.
Publicado: (2020) -
Partnering With State Health Departments to Address Injection-Related Infections During the Opioid Epidemic: Experience at a Safety Net Hospital
por: Burns, Rebecca H, et al.
Publicado: (2021) -
Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1
por: Linas, Benjamin P., et al.
Publicado: (2016)